In the general population, slightly elevated thyroid-stimulating hormone levels (2.5–4.5 mIU/L) are not linked to having fatty liver disease once obesity, diabetes, and high blood pressure are taken into account.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis would determine whether the null association between low-normal TSH and MAFLD after metabolic adjustment is consistent across diverse populations.
Systematic review and meta-analysis of population-based cohort studies reporting ORs for MAFLD in TSH 2.5–4.5 mIU/L vs. <2.5 mIU/L, adjusted for BMI, diabetes, and hypertension.
An RCT would test whether lowering TSH in euthyroid individuals reduces fatty liver incidence, testing whether TSH is a direct driver.
Double-blind RCT of 800 euthyroid adults with BMI ≥24 and TSH 2.5–4.5 mIU/L, randomized to levothyroxine (target TSH 1.5–2.0) vs. placebo for 2 years, with primary outcome change in liver fat via MRI-PDFF.
A prospective cohort would determine whether low-normal TSH predicts incident MAFLD after accounting for metabolic syndrome development over time.
Prospective cohort of 5,000 adults without MAFLD at baseline, with TSH measured and metabolic syndrome components tracked annually for 5 years, analyzing whether TSH 2.5–4.5 mIU/L predicts incident MAFLD after adjusting for BMI, diabetes, and hypertension.
A case-control study would compare TSH levels between individuals with and without MAFLD, matched for metabolic syndrome components.
Case-control study of 1,000 adults: 500 with MAFLD (MRI-confirmed) and 500 without, matched for BMI, diabetes, and hypertension, measuring TSH at time of diagnosis to compare levels.
A cross-sectional study can only show whether TSH and MAFLD coexist at a single time point, as done in this study.
Cross-sectional analysis of 20,000 adults with TSH and MAFLD (ultrasound-confirmed) measured simultaneously, comparing prevalence across TSH categories before and after adjustment for metabolic syndrome.